在线客服

晓洁:

198-8659-7060

NT2-D1(NTERA-2 clone D1)人睾丸癌细胞[STR鉴定正确]

产品型号:BH-C365
产品规格:1x10^6cell / T25瓶
产品价格:¥4600

返回列表

商品详情相关试剂说明书下载参考文献

商品详情

目录号

BH-C365

细胞英文(简称)

NT2-D1(NTERA-2 clone D1)

细胞名称

NT2-D1(NTERA-2 clone D1); 人睾丸癌细胞【已通过STR鉴定】

背景资料

NT2-D1(NTERA-2 clone D1)是一种表现出上皮样分化变化表型和形态的细胞系,于 1980 年从一位 22 岁白人男性癌症患者的睾丸中分离出来,具有恶性多能性胚胎。

细胞来源

ATCC

代次

P3

规格

冻存管/培养瓶

细胞数

1x10^6 cells

生物安全级别

1

组织来源

睾丸癌

细胞形态

贴壁;上皮细胞样

细胞活力

95%(Viability by Trypan Blue Exclusion

细胞检测

细胞不含有HIV-1HBVHCV、支原体、细菌、酵母和真菌

培养条件

DMEM(高糖) +10% FBS(货号:C2056-1A+1%P/S37℃5% CO2

传代方法

首次建议1:2-1:3 两天换液一次

冻存条件

无血清细胞冻存液(货号:S002

相关试剂

参考文献

PubMed=6144603; DOI=10.1016/0012-1606(84)90316-6
Andrews P.W.
Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro.
Dev. Biol. 103:285-293(1984)

PubMed=6694356
Andrews P.W., Damjanov I., Simon D., Banting G.S., Carlin C.R., Dracopoli N.C., Fogh J.
Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro.
Lab. Invest. 50:147-162(1984)

PubMed=3293662; DOI=10.1016/0304-419X(88)90003-0
Andrews P.W.
Human teratocarcinomas.
Biochim. Biophys. Acta 948:17-36(1988)

PubMed=8242627
Timmer-Bosscha H., Timmer A., Meijer C., de Vries E.G.E., de Jong B., Oosterhuis J.W., Mulder N.H.
cis-diamminedichloroplatinum(ii) resistance in vitro and in vivo in human embryonal carcinoma cells.
Cancer Res. 53:5707-5713(1993)

PubMed=8411264; DOI=10.1002/jnr.490350603
Pleasure S.J., Lee V.M.-Y.
NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell.
J. Neurosci. Res. 35:585-602(1993)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=24812411; DOI=10.1158/1078-0432.CCR-13-2868
Feldman D.R., Iyer G., Van Alstine L., Patil S., Al-Ahmadie H., Reuter V.E., Bosl G.J., Chaganti R.S.K., Solit D.B.
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Clin. Cancer Res. 20:3712-3720(2014)

PubMed=25802994; DOI=10.1177/026119291504300105
Jasnic-Savovic J., Klajn A., Milivojevic M., Mojsin M., Nikcevic G.
Human embryonal carcinoma cells in serum-free conditions as an in vitro model system of neural differentiation.
Altern. Lab. Anim. 43:9-18(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

联系我们
  • 19886597060